Journal of Gastroenterology

, Volume 50, Issue 4, pp 424–434 | Cite as

Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers

  • Masau Sekiguchi
  • Ryoji Kushima
  • Ichiro Oda
  • Haruhisa Suzuki
  • Hirokazu Taniguchi
  • Shigeki Sekine
  • Takeo Fukagawa
  • Hitoshi Katai
Original Article—Alimentary Tract



We recently reported that the presence of a papillary adenocarcinoma (pap) component was an independent risk factor for lymphatic involvement in endoscopically resected early gastric cancer (EGC). This study aimed to investigate the potential association between the presence of a pap component in EGC and lymph node metastasis (LNM).


In order to evaluate the association between LNM and clinicopathological features, including a pap component, we reviewed 628 surgically resected EGCs at our institution between 2009 and 2012. Clinicopathological features included age, gender, tumor location, macroscopic type, tumor size, histological type, depth, ulcerative findings, and lymphatic and venous involvement. In addition, the association between clinicopathological features and lymphatic involvement was also evaluated.


LNM was observed in 52 cases (8.3%). Univariate analyses revealed a significant correlation between a pap component and LNM as well as tumor size, depth, macroscopic type, a poorly differentiated adenocarcinoma component, and lymphatic and venous involvement. The percentage of positive LNM among the EGC cases with a pap component was significantly higher than in those without the component (18.2 vs. 7.3%, P = 0.010). Via multivariate analyses lymphatic involvement was identified as the strongest risk factor for LNM [odds ratio (OR) 14.1] and a pap component was revealed as an independent risk factor for lymphatic involvement (OR 3.1).


Our study revealed that EGC cases with a pap component were at higher risk of lymphatic involvement and showed a higher percentage of positive LNM. More attention should be paid to a pap component in EGC.


Early gastric cancer Lymph node metastasis Lymphatic involvement Papillary adenocarcinoma 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Rembacken BJ, Gotoda T, Fujii T, et al. Endoscopic mucosal resection. Endoscopy. 2001;33:709–18.CrossRefPubMedGoogle Scholar
  2. 2.
    Soetikno RM, Gotoda T, Nakanishi Y, et al. Endoscopic mucosal resection. Gastrointest Endosc. 2003;57:567–79.CrossRefPubMedGoogle Scholar
  3. 3.
    Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48:225–9.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Oda I, Gotoda T, Hamanaka H, et al. Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. Dig Endosc. 2005;17:54–8.CrossRefGoogle Scholar
  5. 5.
    Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer. 2006;9:262–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamao T, Shirao K, Ono H, et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer. 1996;77:602–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Kurihara N, Kubota T, Otani Y, et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg. 1998;85:835–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Gotoda T, Sasako M, Ono H, et al. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg. 2001;88:444–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd english edition. Gastric Cancer. 2011;14:101–12.CrossRefGoogle Scholar
  11. 11.
    Association Japanese Gastric Cancer. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRefGoogle Scholar
  12. 12.
    Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumors of the digestive system. 4th ed. Lyon: IARC; 2010. p. 48–58.Google Scholar
  13. 13.
    Nishida T, Tanaka S, Haruma K, et al. Histologic grade and cellular proliferation at the deepest invasive portion correlate with the high malignancy of submucosal invasive gastric carcinoma. Oncology. 1995;52:340–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Yasuda K, Adachi Y, Shiraishi N, et al. Papillary adenocarcinoma of the stomach. Gastric Cancer. 2000;3:33–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Koseki K, Takizawa T, Koike M, et al. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Sekiguchi M, Sekine S, Oda I, et al. Risk factors for lymphatic and venous involvement in endoscopically resected gastric cancer. J Gastroenterol. 2013;48:706–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  18. 18.
    Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Kaizaki Y, Hosokawa O, Miyanaga T, et al. Pathological characteristics of early gastric cancer with mixed histological types. Stomach and Intestine. 2013;48:1539–51 (in Japanese).Google Scholar
  20. 20.
    Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRefPubMedGoogle Scholar
  21. 21.
    Noguchi Y. Blood vessel invasion in gastric carcinoma. Surgery. 1990;107:140–8.PubMedGoogle Scholar
  22. 22.
    Arigami T, Natsugoe S, Uenosono Y, et al. Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer. 2005;93:688–93.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Sako A, Kitayama J, Ishikawa M, et al. Impact of immunohistochemically identified lymphatic invasion on nodal metastasis in early gastric cancer. Gastric Cancer. 2006;9:295–302.CrossRefPubMedGoogle Scholar
  24. 24.
    Yonemura Y, Endou Y, Tabachi K, et al. Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40. Hum Pathol. 2006;37:1193–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Luinetti O, Fiocca R, Villani L, et al. Genetic pattern, histological structure, and cellular phenotype in early and advanced gastric cancers: evidence for structure-related genetic subsets and for loss of glandular structure during progression of some tumors. Hum Pathol. 1998;29:702–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Arai T, Esaki Y, Inoshita N, et al. Pathologic characteristics of gastric cancer in the elderly: a retrospective study of 994 surgical patients. Gastric Cancer. 2004;7:154–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Ha TK, An JY, Youn HK, et al. Indication for endoscopic mucosal resection in early signet ring cell gastric cancer. Ann Surg Oncol. 2008;15:508–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim HM, Pak KH, Chung MJ, et al. Early gastric cancer of signet ring cell carcinoma is more amenable to endoscopic treatment than is early gastric cancer of poorly differentiated tubular adenocarcinoma in select tumor conditions. Surg Endosc. 2011;25:3087–93.CrossRefPubMedGoogle Scholar
  30. 30.
    Shiroshita H, Watanabe H, Ajioka Y, et al. Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. Pathol Int. 2004;54:311–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Shibata N, Watari J, Fujiya M, et al. Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype. Hum Pathol. 2003;34:32–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Nakamoto J, Torisu R, Aoki R, et al. Clinicopathological evaluation of biological behavior of submucosal invasive gastric carcinomas: relationship among lymph node metastasis, mucin phenotype and proliferative activity. J Med Invest. 2007;54:99–108.CrossRefPubMedGoogle Scholar
  33. 33.
    Guo RJ, Arai H, Kitayama Y, et al. Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa. Pathol Int. 2001;51:240–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Song JP, Kitayama Y, Igarashi H, et al. Centromere numerical abnormality in the papillary, papillotubular type of early gastric cancer, a further characterization of a subset of gastric cancer. Int J Oncol. 2002;21:1205–11.PubMedGoogle Scholar
  35. 35.
    Arai T, Sakurai U, Sawabe M, et al. Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach. Gastric Cancer. 2013;16:505–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Masau Sekiguchi
    • 1
    • 2
  • Ryoji Kushima
    • 2
  • Ichiro Oda
    • 1
  • Haruhisa Suzuki
    • 1
  • Hirokazu Taniguchi
    • 2
  • Shigeki Sekine
    • 3
  • Takeo Fukagawa
    • 4
  • Hitoshi Katai
    • 4
  1. 1.Endoscopy DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Pathology DivisionNational Cancer Center HospitalTokyoJapan
  3. 3.Molecular Pathology DivisionNational Cancer Center Research InstituteTokyoJapan
  4. 4.Gastric Surgery DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations